Summer Doldrums Set In as Latigo (LTGO) And BlossomHill (BLSM) Close Out a Quieter Week
Latigo surrendered most of its opening premium while BlossomHill finished back at its IPO price, as the new-issue market loses some seasonal...
101 Views
Latigo Biotherapeutics (LTGO): IPO Gets a Healthy Start, Then Loses Its Pain Relief
​Latigo's IPO reflects strong institutional demand, with stock opening high but closing slightly above IPO price. Phase 3 development of LTG-001...
147 Views
Latigo Biotherapeutics (LTGO): Taking the Sting Out of Pain: Latigo Draws IPO Demand
​LTG-001 shows promise as a fast-acting, opioid-sparing therapy for acute pain, with strong market debut expected thanks to high-quality sponsorship.
116 Views
IPO Databook: Latigo Biotherapeutics (LTGO US) - Aug 2026
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines. Their initial focus...
99 Views
Latigo Biotherapeutics (LTGO) Eyes $272 Million IPO to Advance Non-Opioid Pain Medicines
Clinical-stage biotechnology company advancing a pipeline of Nav1.8 inhibitors designed to deliver effective pain relief without the risk of opioid...
129 Views